Multiple Myeloma

10 protocols meet the specified criteria.

  • 68284528MMY4006

    Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene autoleucel (cilta-cel) Out-of-Specification (OOS) in patients with Multiple Myeloma

  • A151804

    Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

  • A211901

    Reaching Rural Cancer Survivors Who Smoke Using Test-Based Cessation Interventions

  • BB2121-EAP-001

    Expanded Access Protocol (EAP) for Subjects Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release

  • EAA173

    Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma

  • EAY191

    Molecular Analysis for Combination Therapy Choice (ComboMATCH)

  • GRAIL-MA-002

    REACH Study: Real-world Evidence to Advance Multi-Cancer Early Detection Health Equity (REACH/Galleri-Medicare study)

  • JCAR017-EAP-001

    Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel that is Nonconforming for Commercial Release

  • KT-US-472-0141

    Expanded access to commercially out-of-specification brexucabtagene autoleucel for the treatment of adult patients diagnosed with an FDA approved labeled indication

  • WVU010922

    Prospective Evaluation of Xerava (Eravacycline) Prophylaxis in Hematological Malignancy Patients with Prolonged Neutropenia